Kontour Medical 2026H1: Net Profit Attributable to Shareholders of the Parent Company Decreased by 24.74% YoY, R&D Investment Surge of 74% Pressures Profitability.

Source: Kangtuo Medical 2026 Semi-Annual Report

Operating revenue of RMB 171 million / PEEK material series achieved revenue of RMB 113 million / Overseas market sales revenue decreased by 1.44% year-on-year

DentalGoodNews｜August 28, 2026, Kontour(Xi'an) Medical Technology Co.,Ltd. (hereinafter referred to as "Kontour Medical") released its 2026 semi-annual report. During the reporting period, the company achieved operating revenue of RMB 171 million, a slight increase of 0.38% year-on-year; net profit attributable to shareholders of the listed company was RMB 41.3937 million, a decrease of 24.74% year-on-year. Net profit attributable to shareholders of the parent company after deducting non-recurring gains and losses was RMB 37.6941 million, down 25.19% year-on-year.

Source: Kangtuo Medical 2026 Semi-Annual Report

By business segment, the company's core product, the PEEK material series, achieved revenue of RMB 113 million, a year-on-year increase of 4.06%, with its revenue share rising from 63.87% in the same period last year to 66.21%. Meanwhile, revenue from traditional titanium material products recorded RMB 30.3732 million, a year-on-year decrease of 20.88%. The company stated that PEEK material products, leveraging advantages such as high personalized fit, excellent imaging compatibility, and biomechanical properties close to autologous bone, are substituting titanium materials, with penetration of high-end products continuing to increase.

In terms of segment market performance, Kontour Medical's "HuanTi" craniomaxillofacial repair brand achieved revenue of RMB 11.5553 million in the first half of the year, a year-on-year increase of 128.23%. Its share of main business revenue rose from 3.05% in the same period last year to 7.04%, an increase of 3.99 percentage points year-on-year.

In the international market, the company achieved overseas sales revenue of RMB 17.4986 million, a year-on-year decrease of 1.44%. During the reporting period, 5 new overseas registration certificates were obtained, covering 4 countries. Among them, three core products — the 4D bioactive plate, PEEK connector plate, and PEEK screw — have completed the submission of FDA registration applications as planned.

Kontour Medical's 4D bioactive plate achieved revenue of RMB 8.2385 million during the reporting period, a year-on-year increase of 253.12%. The company stated that with the continuous accumulation of clinical surgical cases, this product, along with the all-PEEK skull repair solution as core promotion categories, is seeing steady improvement in clinical recognition and market acceptance.

Source: Kangtuo Medical 2026 Semi-Annual Report

According to previous reports by DGN, Kontour Medical completed the acquisition of Xi'an Salamander Biotechnology in 2025, aiming to build an integrated solution covering the entire dental implantation process. In this semi-annual report, the consolidation of Xi'an Salamander Biotechnology's financials and the increase in management personnel compensation led to a significant year-on-year increase of 39.21% in the company's administrative expenses, reaching RMB 34.4108 million. In addition, the share-based payment expenses for equity incentives recognized in the current period also exerted certain pressure on profits. Excluding the impact of related share-based payment expenses, net profit attributable to shareholders of the listed company was RMB 46.5941 million, with the year-on-year decline narrowing to 16.02%.

Increased R&D investment was another factor contributing to the profit decline. During the reporting period, Kontour Medical's expensed R&D investment reached RMB 18.5633 million, an increase of 74.31% year-on-year, with R&D investment as a percentage of operating revenue rising from 7.88% to 11.60%. The financial report noted that the increase in R&D expenses was mainly attributable to certain ongoing research projects entering the design verification stage, resulting in increased material costs and testing expenses, increased share-based payment expenses for R&D personnel, and the inclusion of subsidiary Xi'an Salamander Biotechnology in the consolidated financial statements.

In terms of asset quality, as of the end of the period, the company's total assets were RMB 932 million, and net assets attributable to shareholders of the listed company were RMB 746 million. Net cash flow from operating activities was RMB 59.6084 million, maintaining a good match with the profit scale. The company plans to distribute a cash dividend of RMB 1.50 per 10 shares (tax inclusive) to all shareholders, with a total expected cash dividend distribution of approximately RMB 12.2442 million.

In addition, the financial report disclosed that the number of companies obtaining registration certificates for domestic oral membranes and bone repair materials continues to expand. Industry oversupply and intensifying price competition, coupled with the normalized implementation of volume-based procurement for dental implants, continue to put pressure on terminal prices, squeezing the company's oral business revenue and profit margins. The financial report mentioned that although the company's self-developed dental implants, "absorbable dental membrane," and "oral bone repair materials" have formed product synergy and integrated diagnosis and treatment solutions, homogeneous competition among existing products has limited performance growth. The company plans to accelerate the iteration and commercial deployment of differentiated new products such as additively manufactured dental implants and supporting accessories.